|
1
|
Leitzmann MF and Rohrmann S: Risk factors
for the onset of prostatic cancer: Age, location, and behavioral
correlates. Clin Epidemiol. 4:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Felgueiras J, Silva JV and Fardilha M:
Prostate cancer: The need for biomarkers and new therapeutic
targets. J Zhejiang Univ Sci B. 15:16–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
da Silva HB, Amaral EP, Nolasco EL, de
Victo NC, Atique R, Jank CC, Anschau V, Zerbini LF and Correa RG:
Dissecting major signaling pathways throughout the development of
prostate cancer. Prostate Cancer. 2013:9206122013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frank SB and Miranti CK: Disruption of
prostate epithelial differentiation pathways and prostate cancer
development. Front Oncol. 3:2732013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho JY, Lee M, Ahn JM, et al: Proteomic
analysis of a PDEF Ets transcription factor-interacting protein
complex. J Proteome Res. 8:1327–1337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steffan JJ and Koul HK: Prostate derived
ETS factor (PDEF): a putative tumor metastasis suppressor. Cancer
Lett. 310:109–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oh S, Shin S and Janknecht R: ETV1, 4 and
5: an oncogenic subfamily of ETS transcription factors. Biochim
Biophys Acta. 1826:1–12. 2012.PubMed/NCBI
|
|
9
|
Hsu T, Trojanowska M and Watson DK: Ets
proteins in biological control and cancer. J Cell Biochem.
91:896–903. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson TR, Koul S, Kumar B, Khandrika L,
Venezia S, Maroni PD, Meacham RB and Koul HK: Loss of PDEF, a
prostate-derived Ets factor is associated with aggressive phenotype
of prostate cancer: Regulation of MMP 9 by PDEF. Mol Cancer.
9:1482010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feldman RJ, Sementchenko VI, Magda M,
Fraig MM and Watson DK: Pdef expression in human breast cancer is
correlated with invasive potential and altered gene expression.
Cancer Res. 63:4626–4631. 2003.PubMed/NCBI
|
|
12
|
Ghadersohi A, Odunsi K, Zhang S, Azrak RG,
Bundy BN, Manjili MH and Li F: Prostate-derived Ets transcription
factor as a favorable prognostic marker in ovarian cancer patients.
Int J Cancer. 123:1376–1384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pal M, Koul S and Koul HK: The
transcription factor sterile alpha motif (SAM) pointed
domain-containing ETS transcription factor (SPDEF) is required for
E-cadherin expression in prostate cancer cells. J Biol Chem.
288:12222–12231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paner GP, Luthringer DJ and Amin MB: Best
practice in diagnostic immunohistochemistry: Prostate carcinoma and
its mimics in needle core biopsies. Arch Pathol Lab Med.
132:1388–1396. 2008.PubMed/NCBI
|
|
15
|
Horst D, Gu X, Bhasin M, Yang Q, Verzi M,
Lin D, Joseph M, Zhang X, Chen W, Li YP, Shivdasani RA and
Libermann TA: Requirement of the epithelium-specific Ets
transcription factor Spdef for mucous gland cell function in the
gastric antrum. J Biol Chem. 285:35047–3555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oettgen P, Dedo E, Sun Z, et al: PDEF, a
novel prostate epithelium-specific ets transcription factor,
interacts with the androgen receptor and activates
prostate-specific antigen gene expression. J Biol Chem.
275:1216–1225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsui KH, Chung LC, Feng TH, Chang PL and
Juang HH: Upregulation of prostate-derived Ets factor by luteolin
causes inhibition of cell proliferation and cell invasion in
prostate carcinoma cells. Int J Cancer. 130:2812–2823. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steffan JJ, Koul S, Meacham RB and Koul
HK: The transcription factor SPDEF suppresses prostate tumor
metastasis. J Biol Chem. 287:29968–29978. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rahim S and Uren A: Emergence of ETS
transcription factors as diagnostic tools and therapeutic targets
in prostate cancer. Am J Transl Res. 5:254–268. 2013.PubMed/NCBI
|
|
20
|
Tomlins SA, Rhodes DR, Perner S, et al:
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in
prostate cancer. Science. 310:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakajima Y, Madhyastha R and Maruyama M:
2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase,
regulates tumor angiogenesis and progression. Anticancer Agents Med
Chem. 9:239–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Desgranges C, Razaka G, Rabaud M, Picard
P, Dupuch F and Bricaud H: The human blood platelet: a cellular
model to study the degradation of thymidine and its inhibition.
Biochem Pharmacol. 31:2755–2759. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Friedkin M and Roberts D: The enzymatic
synthesis of nucleosides. I. Thymidine phosphorylase in mammalian
tissue. J Biol Chem. 207:245–256. 1954.PubMed/NCBI
|
|
24
|
Brown NS, Jones A, Fujiyama C, Harris AL
and Bicknell R: Thymidine phosphorylase induces carcinoma cell
oxidative stress and promotes secretion of angiogenic factors.
Cancer Res. 60:6298–6302. 2000.PubMed/NCBI
|
|
25
|
Hotchkiss KA, Ashton AW and Achwartz EL:
Thymidine phosphorylase and 2-deoxyribose stimulate human
endothelial cell migration by specific activation of the integrins
alpha 5 beta 1 and alpha V beta 3. J Biol Chem. 278:19272–19279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bronckaers A, Gago F, Balzarini J and
Liekens S: The dual role of thymidine phosphorylase in cancer
development and chemotherapy. Med Res Rev. 29:903–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pizzorno G, Cao D, Leffert JJ, Russell RL,
Zhang D and Handschumacher RE: Homeostatic control of uridine and
the role of uridine phosphorylase: A biological and clinical
update. Biochim Biophys Acta. 1587:133–144. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao D, Leffert JJ, McCabe J, Kim B and
Pizzorno G: Abnormalities in uridine homeostatic regulation and
pyrimidine nucleotide metabolism as a consequence of the deletion
of the uridine phosphorylase gene. J Biol Chem. 280:21169–21175.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao D, Russell RL, Zhang D, Leffert JJ and
Pizzorno G: Uridine phosphorylase (-/-) murine embryonic stem cells
clarify the key role of this enzyme in the regulation of the
pyrimidine salvage pathway and in the activation of
fluoropyrimidines. Cancer Res. 62:2313–2317. 2002.PubMed/NCBI
|
|
30
|
Kawamura K, Takiguchi N, Wada A, Takenobu
H, Kimura H, Soda H, Nagata M, Asano T and Tagawa M: Up-regulated
expression of the uridine phosphorylase gene in human gastric
tumors is correlated with a favorable prognosis. Anticancer Res.
26:4647–4651. 2006.PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-deltadelta C(t)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu D, Li XF, Zheng S and Jiang WZ:
Quantitative real-time RT-PCR detection for CEA, CK20 and CK19 mRNA
in peripheral blood of colorretal cancer patients. J Zhejiang Univ
SCIENCEB. 7:445–451. 2006. View Article : Google Scholar
|
|
33
|
Kheirelseid EA, Chang KH, Newell J, Kerin
MJ and Miller N: Identification of endogenous control genes for
normalization of real-time quantitative PCR data in colorectal
cancer. Mol Biol. 11:1–13. 2010.
|
|
34
|
Moussa O, Turner DP, Feldman RJ,
Sementchenko VI, McCarragher BD, Desouki MM, Fraig M and Watson DK:
PDEF is a negative regulator of colon cancer cell growth and
migration. J Cell Biochem. 108:1389–1398. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gunawardane RN, Sgroi DC, Wrobel CN, Koh
E, Daley GQ and Brugge JS: Novel role for PDEF in epithelial cell
migration and invasion. Cancer Res. 65:11572–11580. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rodabaugh KJ, Mhawech-Fauceglia P, Groth
J, Lele S and Sood AK: Prostate-derived Ets factor is overexpressed
in serous epithelial ovarian tumors. Int J Gynecol Pathol.
26:10–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sood AK, Saxena R, Groth J, Desouki MM,
Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS and Geradts J:
Expression characteristics of prostate-derived Ets factor support a
role in breast and prostate cancer progression. Hum Pathol.
38:1628–1638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ghadersohi A and Sood AK: Prostate
epithelium-derived Ets transcription factor mRNA is overexpressed
in human breast tumors and is a candidate breast tumor marker and a
breast tumor antigen. Clin Cancer Res. 7:2731–2738. 2001.PubMed/NCBI
|
|
39
|
Nozawa M, Yomogida K, Kanno N, Nonomura N,
Miki T, Okuyama A, Nishimune Y and Nozaki M: Prostate-specific
transcription factor hPSE is translated only in normal prostate
epithelial cells. Cancer Res. 60:1348–1352. 2000.PubMed/NCBI
|
|
40
|
Turner DP, Findlay VJ, Moussa O,
Semenchenko VI, Watson PM, LaRue AC, Desouki MM, Fraig M and Watson
DK: Mechanisms and functional consequences of PDEF protein
expression loss during prostate cancer progression. Prostate.
71:1723–1735. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang JJ, Liu YX, Wang W, Yan W, Zheng YP,
Qiao LD, Liu D and Chen S: Fusion between TMPRSS2 and ETS family
members (ERG, ETV1, ETV4) in prostate cancers from northern China.
Asian Pac J Cancer Prev. 13:4935–4938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aytes A, Mitrofanova A, Kinkade CW, et al:
ETV4 promotes metastasis in response to activation of PI3kinase and
Ras signaling in a mouse model ofadvanced prostate cancer. Proc
Natl Acad Sci USA. 110:E3506–E3515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Taylor BS, Schultz N, Hieronymus H, et al:
Integrative genomic profiling of human prostate cancer. Cancer
Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Span PN, Manders P, Heuvel JJ, Beex LV and
Sweep CG: E1AF expression levels are not associated with prognosis
in human breast cancer. Breast Cancer Res Treat. 79:129–131. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xia WY, Lien HC, Wang SC, et al:
Expression of PEA3 and lack of correlation between PEA3 and
HER-2/neu expression in breast cancer. Breast Cancer Res Treat.
98:295–301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Clark JP and Cooper CS: ETS gene fusions
in prostate cancer. Nat Rev Urol. 6:429–439. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Takebayashi Y, Akiyama S, Akiba S, Yamada
K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T:
Clinicopathologic and prognostic significance of an angiogenic
factor, thymidine phosphorylase, in human colorectal carcinoma. J
Natl Cancer Inst. 88:1110–1117. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Imazano Y, Takebayashi Y, Nishiyama K,
Akiba S, Miyadera K, Yamada Y, Akiyama S and Ohi Y: Correlation
between thymidine phosphorylase expression and prognosis in human
renal cell carcinoma. J Clin Oncol. 15:2570–2578. 1997.PubMed/NCBI
|
|
49
|
Shimaoka S, Matsushita S, Nitanda T,
Matsuda A, Nioh T, Suenaga T, Nishimata Y, Akiba S, Akiyama S and
Nishimata H: The role of thymidine phosphorylase expression in the
invasiveness of gastric carcinoma. Cancer. 88:2220–2227. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu M, Cao D, Russell R, Handschumacher RE
and Pizzorno G: Expression, characterization, and detection of
human uridine phosphorylase and identification of variant uridine
phosphorolytic activity in selected human tumors. Cancer Res.
58:5418–5424. 1998.PubMed/NCBI
|
|
51
|
Maehara Y, Sakaguchi Y, Kusumoto T,
Kusumoto H and Sugimachi K: Species differences in substrate
specificity of pyrimidine nucleoside phosphorylase. J Surg Oncol.
42:184–186. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Thompson IM, Ankerst DP, Chi C, Goodman
PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL and Coltman CA Jr:
Assessing prostate cancer risk: Results from the Prostate Cancer
Prevention Trial. J Natl Cancer Inst. 98:529–534. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Picard JC, Golshayan AR, Marshall DT,
Opfermann KJ and Keane TE: The multi-disciplinary management of
high-risk prostate cancer. Urol Oncol. 30:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rampazzo C, Miazzi C, Franzolin E,
Pontarin G, Ferraro P, Frangini M, Reichard P and Bianchi V:
Regulation by degradation, a cellular defense against
deoxyribonucleotide pool imbalances. Mutat Res. 703:2–10. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Roosild TP, Castronovo S, Villoso A,
Ziemba A and Pizzorno G: A novel structural mechanism for redox
regulation of uridine phosphorylase 2 activity. J Struct Biol.
176:229–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kobayashi Y, Wada Y, Ohara T, Okuda Y,
Suzuki N, Hasegawa K, Kiguchi K and Ishizuka B: Enzymatic
activities of uridine and thymidine phosphorylase in normal and
cancerous uterine cervical tissues. Hum Cell. 20:107–110. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yasuno M, Mori T, Koike M, Takahashi K,
Toi M, Takizawa T, Shimizu S, Yamaguchi T and Matsumoto H:
Importance of thymidine phosphorylase expression in tumor stroma as
a prognostic factor in patients with advanced colorectal carcinoma.
Oncol Rep. 13:405–412. 2005.PubMed/NCBI
|
|
58
|
Oppenheim JJ, Zachariae CO, Mukaida N and
Matsushima K: Properties of the novel proinflammatory supergene
intercrine cytokine family. Annu Rev Immunol. 9:617–621. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Takahashi Y, Bucana CD, Liu W, Yoneda J,
Kitadai Y, Cleary KR and Ellis LM: Platelet-derived endothelial
cell growth factor in human colon cancer angiogenesis: Role of
infiltrating cells. J Natl Cancer Inst. 88:1146–1151. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cao D, Ziemba A, McCabe J, Yan R, Wan L,
Kim B, Gach M, Flynn S and Pizzorno G: Differential expression of
uridine phosphorylase in tumors contributes to an improved
fluoropyrimidine therapeutic activity. Mol Cancer Ther.
10:2330–2339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Brown NS and Bicknell R: Thymidine
phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J.
334:1–8. 1998.PubMed/NCBI
|
|
62
|
Di Napoli A and Signoretti S: Tissue
biomarkers in renal cell carcinoma: Issues and solutions. Cancer.
115:2290–2297. 2009. View Article : Google Scholar : PubMed/NCBI
|
